Catalent (NYSE:CTLT) is selling its oral solids development and small-scale manufacturing facility in Somerset, New Jersey to ...

The site also serves as an oral solids development and small-scale manufacturing facility for the pharmaceutical company, ...

Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, ...

Awaiting a potential acquisition by Novo Holdings, Catalent is giving its contract manufacturing compatriot a boost as Ardena ...

CTLT announces an agreement to sell its oral solids development and manufacturing facility in Somerset to Ardena.

Catalent has agreed to sell its oral drug development and small-scale manufacturing facility in Somerset, New Jersey to ...

Catalent entered into a definitive agreement to sell its oral solids development and small-scale manufacturing facility in ...

Catalent, Inc. (CTLT), a provider of advanced delivery technologies and development solutions for drugs, biologics, and consumer ...

Ardena inks agreement to acquire Catalent’s state-of-the-art facility in Somerset, New Jersey: Ghent, Belgium Tuesday, October 15, 2024, 16:00 Hrs [IST] Ardena, a specialist pha ...

SOMERSET, N.J.--(BUSINESS WIRE)-- Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, announced today that it has entered ...

SOMERSET, N.J., August 29, 2024--Catalent, Inc. (NYSE: CTLT), the leader in enabling the development and supply of better treatments for patients worldwide, today announced financial results for ...

SOMERSET, N.J. (AP) — SOMERSET, N.J. (AP) — Catalent Inc. (CTLT) on Thursday reported fiscal fourth-quarter net income of $23 million. The Somerset, New Jersey-based company said it had profit ...